Stanford Pituitary Center Clinical Trials

An Open Label, Multi-Center Pasireotide Roll-Over Protocol for Patients who have Completed a Previous Novartis Sponsored Pasireotide Study and are Judged by the Investigator to Benefit from Continued Pasireotide Treatment

Status: Closed to Recruitment, Activities Continuing
PI: Laurence Katznelson, MD
NCT01794793
Contact: Bharati Sanjanwala
bharatis@stanford.edu

An Open-Label, Dose Finding, International Phase 2 Study with Once Monthly Subcutaneous Somavaratan in Adult Growth Hormone Deficiency (GHD) [Versartis International Trial in Adults with Long Acting Growth Hormone:The VITAL study]

Status: Closed to Recruitment, Activities Continuing
PI: Laurence Katznelson, MD
NCT02526420
Contact: Bharati Sanjanwala
bharatis@stanford.edu

Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in AGHD

Status: Closed
PI: Laurence Katznelson, MD
NCT02719990
Contact: Bharati Sanjanwala
bharatis@stanford.edu

A Phase 3, Randomized, Open-Label, Active Controlled, Multicenter Study To Evaluate Maintenance Of Response, Safety and Patient Reported Outcomes in Acromegaly Patients Treated with Octreotide Capsules, and in Patients Treated with Standard of Care Parenteral Somatostatin Receptor Ligands Who Previously Tolerated and Demonstrated a Biochemical Control on Both Treatments

Status: Recruiting
PI: Laurence Katznelson, MD
NCT not available yet
Contact: Bharati Sanjanwala
bharatis@stanford.edu

Questions?

Contact: Bharati Sanjanwala
bharatis@stanford.edu